Document is current
Any future updates will be listed below
-
Authors
Fernández de Larrea-Baz, Nerea
Pérez-Gómez, Beatriz http://orcid.org/0000-0002-4299-8214
Guerrero-Zotano, Ángel
Casas, Ana María
Bermejo, Begoña
Baena-Cañada, José Manuel
Antolin, Silvia
Sánchez-Rovira, Pedro
Ramos Vázquez, Manuel
Garcia-Sáenz, José Ángel http://orcid.org/0000-0001-6880-0301
Antón, Antonio
Muñoz, Montserrat
de Juan, Ana
Jara, Carlos
Chacón, José Ignacio
Arcusa, Angels
Gil-Gil, Miguel
Adrover, Encarna
Oltra, Amparo
Brunet, Joan http://orcid.org/0000-0003-1945-3512
González, Sonia
Bezares, Susana
Lope, Virginia
Martín, Miguel http://orcid.org/0000-0001-9237-3231
Pollán, Marina
-
Funding
Funding for this research was provided by:
Fundación Científica Asociación Española Contra el Cáncer
Sociedad Española de Oncología Médica (SEOM)
Fundación Cerveza y Salud 2005
- License Information
-
More Information
Article History
Received: 16 September 2019
Accepted: 2 April 2020
First Online: 8 May 2020
Competing interests
: Competing interests:B.B. has received consulting/advisory fees from Roche, Novartis and Pfizer. R.V.M. has received consultancy/speaker fees from Astra Zeneca, Novartis, Roche, and Pfizer. J.A.G.S. has received consultancy/speaker fees from Novartis, Celgene, Eli Lilly, EISAI, and Roche, Institution research funding from Astrazeneca, and travel support from Novartis, Roche, and Pfizer. M.G.G. has received honoraria or travel support to attend scientific meeting from Pfizer, Novartis, Daiichi, Roche, and Genomic Health. M.Ma. has received research grants from Roche, PUMA and Novartis, consulting/advisory fees from AstraZeneca, Amgen, Taiho Oncology, Roche/Genentech, Novartis, PharmaMar, Eli Lilly, PUMA, Taiho Oncology and Pfizer and speakers’ honoraria from AstraZeneca, Amgen, Roche/Genentech, Novartis, Daiichi Sankyo and Pfizer. The remaining authors declare no potential conflict of interest.
